Pharmacy India
Pharmacy India is your ultimate destination for pharmacy exam preparation and career advancement. Discover top-notch study materials, daily quizzes, and expert courses for pharmacy exams like RRB Pharmacist, GPAT, and NIPER JEE, D.Pharma Exit Exam, etc.
The Drugs Consultative Committee (DCC) has recently undertaken a comprehensive examination into the potential misuse of opioid pain-relief medicine tapentadol and the anticonvulsant and analgesic drug pregabalin. This blog post delves into the committee’s decisions and considerations, shedding light on the recommendations for potential control measures on the sales of these drugs in the market.
In a recent development, the Union health ministry’s draft National Pharmacy Commission (NPC) Bill 2023 faces opposition from the Student Pharmacists Rights Committee (SPRC) in Maharashtra. The SPRC has passed a resolution urging the Union government to reconsider its move to create the NPC, emphasizing the importance of retaining the Pharmacy Council of India (PCI).
The Food Safety and Drug Control Administration (FSDCA) in Rajasthan has unearthed a shocking revelation, exposing 101 fraudulent registrations of pharmacists enlisted with the Rajasthan State Pharmacy Council (RSPC). This significant discovery comes after numerous complaints were received by the…
In a significant move towards global vaccine quality benchmarks, the Drugs Consultative Committee (DCC) has called upon all Indian states to provide crucial data on vaccine manufacturing and sales. The World Health Organization (WHO) mandates this data for its Global Benchmarking Tool (GBT) assessment, a prerequisite for UN agencies to procure vaccines from Indian manufacturers.
In a significant move aimed at enhancing patient safety and awareness, the Drugs Consultative Committee (DCC) under the Union health ministry has recommended amendments to the regulation mandating Quick Response (QR) codes for the top 300 drug brands. The proposed change includes comprehensive information on all excipients used in the drug formulation.
In a decisive move to tackle quality issues in pharmaceutical excipients, the Drugs Consultative Committee (DCC) of the Union health ministry has recommended stringent measures. The recent meeting, chaired by Drugs Controller General of India (DCGI) Dr Rajeev Singh Raghuvanshi, emphasized the necessity of adhering to the Drugs and Cosmetics Act for the use of only pharma-grade excipients.
In the dynamic landscape of healthcare, medical representatives serve as vital bridges between pharmaceutical companies and healthcare professionals. Dr. Sunil S Chiplunkar, Vice President of Business Development at Group Pharmaceuticals, emphasizes the instrumental role played by these representatives in propelling the industry forward.
In a groundbreaking move towards promoting research and validating pragmatic Ayurveda practices, the Central Council for Research in Ayurveda Sciences (CCRAS), under the Ministry of Ayush, has unveiled the ‘Ayurveda Gyan Naipunya Initiative’ (AGNI). This initiative is designed to bolster Ayurveda practitioners by providing a platform to report innovative practices and experiences in diverse disease conditions.
In a recent revelation by the Central Drugs Standard Control Organisation (CDSCO), nearly 5.5% of drug samples tested in October 2023 have been deemed not of standard quality (NSQ). The affected samples include products from well-known pharmaceutical companies such as Intas Pharmaceuticals, Emcure Pharmaceuticals, RPG Life Sciences, and Karnataka Antibiotics and Pharmaceuticals Ltd (KAPL).
In a significant development, the proposed National Pharmacy Commission Bill 2023 is causing ripples within the pharmaceutical community. Dr. BR Jagashetty, former National Adviser (Drugs Control) to the Union health ministry and former Karnataka State Drugs Controller, sheds light on the potential shift in focus from the profession to education in this groundbreaking legislative change.
